Circulating microRNAs, potential biomarkers for drug-induced liver injury

By Kai Wang, Shile Zhang, Bruz Marzolf, Pamela Troisch, A. Brightman, Zhiyuan Hu, Leroy Hood, D. Galas. Proceedings of the National Academy of Sciences of the United States of America, 2009

1,185 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/0fde3ebd65f41cc2220446a0d79011fbdc2d37a3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

Citations in the corpus

Circulating microRNAs are new and sensitive biomarkers of myocardial infarction (2010, background): “The level of some circulating miRNAs has been reported to vary significantly during pregnancy,(12) in the presence of a variety of cancers,(13,14) and in acetaminophen-induced liver damage in the mouse.(15) Studies on circulating miRNAs and heart disease have shown a modulation in a rat model of iso”
Characterization of extracellular circulating microRNA (2011, background): “In a similar way, increase in particular ‘tissue specific’ or ‘organ specific’ miRNAs in blood plasma (or other body fluids) could serve as an indication of toxicity of a particular tissue/organ (10,11).”
Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced and inflammatory liver diseases (2012, result): “Contrary to our observation, Wang et al.(7) reported decreased hepatic miR-122 levels after APAP treatment and this could be due to different APAP doses and timing.”
Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. (2011, background): “It has been reported that large numbers of microRNAs are released to peripheral blood when liver cell damage occurs.(18) Identifying differential circulating microRNAs by contrasting HCC patients with controls as a whole group, which comprises healthy individuals, as well as the patients with hepati”
Comparing the MicroRNA Spectrum between Serum and Plasma (2012, methodology): “For serum or plasma, total RNA was extracted from 100 ml of the sample using the miRNeasy kit (Qiagen, Valencia, CA) as previously described [6,12].”
EASL Clinical Practice Guidelines: Drug-induced liver injury. (2019, background): “In mice, mir-122 and mir-192 are enriched in liver tissue and exhibit dose- and exposure-dependent changes in plasma that parallel serum aminotransferase levels and the histopathology of liver degeneration.(300) In human acetaminophen-induced liver injury, miR-122, miR-192-5p and other miRNAs are el”
Export of microRNAs and microRNA-protective protein by mammalian cells (2010, methodology): “Total RNA including miRNA was isolated using miRNeasy kit (Qiagen, Germantown, MD, USA) with minor modifications that have been described earlier (21).”
Micro‐RNA profiling reveals a role for miR‐29 in human and murine liver fibrosis (2011, background): “Recently, plasma levels of miRNAs have emerged as potential biomarkers for various pathological conditions such as cancers.(13,14) We therefore hypothesized that dysregulation of members of the miR-29 family in fibrotic livers might be associated Fig.”
Circulating microRNAs as Novel Minimally Invasive Biomarkers for Breast Cancer (2010, background): “Previous studies, although few in number, have reported discrepancies between serum and plasma miRNA expression levels, or the investigators have chosen either medium alone for use in their studies.(12,13,16) Finally, a potential relationship between circulating miRNA levels and existing clinicopath”